Lōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisions
Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (
NASDAQ: GCTK), today announced the expansion of its ai² platform into three dedicated business divisions: ai² Pipeline™, ai² Talent™, and ai² Accelerator™. The new structure reflects the growth of the Company's actual intelligence-driven platform and is designed to create opportunities for revenue generation while continuing to advance Lōkahi's core pharmaceutical development strategy.
Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (
NASDAQ: GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the Company's lead development candidate for osteoarthritis pain.
CORRECTING and REPLACING Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline
Please replace the release dated July 31, 2026, with the following corrected version due to multiple minor revisions.
Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (
NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company discussed its proposed clinical strategy for LT-100. Following that meeting, Lōkahi completed a nonclinical minipig study designed to compare systemic exposure following subcutaneous and intradermal administration of LT-100. The results provided important information to support the Company's planned clinical evaluation of a single-injection administration approach.
